Mainz Biomed (NASDAQ:MYNZ) Shares Up 3.4% – Should You Buy?

Mainz Biomed NV (NASDAQ:MYNZ) shares traded up 3.4% during mid-day trading on Monday . The company traded as high as $1.27 and last traded at $1.23. 727,587 shares changed hands during trading, an increase of 96% from the average session volume of 371,589 shares. The stock had previously closed at $1.19.

Mainz Biomed Price Performance

The firm’s fifty day moving average price is $1.98 and its 200 day moving average price is $1.21. The firm has a market capitalization of $11.14 million, a PE ratio of -0.02 and a beta of 0.31. The company has a current ratio of 0.52, a quick ratio of 0.43 and a debt-to-equity ratio of 0.44.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in MYNZ. Armistice Capital LLC boosted its holdings in Mainz Biomed by 45.0% in the second quarter. Armistice Capital LLC now owns 285,000 shares of the company’s stock valued at $402,000 after purchasing an additional 88,400 shares during the last quarter. Cerity Partners LLC purchased a new position in shares of Mainz Biomed during the 4th quarter valued at about $183,000. Finally, Steward Partners Investment Advisory LLC raised its stake in shares of Mainz Biomed by 200.0% during the 4th quarter. Steward Partners Investment Advisory LLC now owns 30,000 shares of the company’s stock valued at $34,000 after buying an additional 20,000 shares during the last quarter.

Mainz Biomed Company Profile

Mainz Biomed AG is a molecular diagnostics company headquartered in Mainz, Germany, specializing in epigenetics-based tests for the early detection of cancer. The company develops proprietary assays that analyze DNA methylation patterns and other epigenetic biomarkers to identify malignancies at a stage when treatment outcomes are most favorable. Mainz Biomed’s technology platform is designed to offer non-invasive, easy-to-use screening solutions that can be deployed both in laboratory settings and at point of care.

The company’s flagship product, ColoAlert®, is a stool-based colorectal cancer screening test that combines DNA methylation markers with bacterial gene targets to improve sensitivity and specificity for detecting advanced adenomas and early-stage colorectal cancer.